Track topics on Twitter Track topics that are important to you
Congestive heart failure CHF is a physiological condition that has an adverse impact on the pumping efficiency of the cardiac muscles. It characterizes the accumulation of fluid around the heart leading to inefficient pumping. The onset of CHF is marked by the failure of the ventricles to pump sufficient volume of blood to the body organs. This eventually leads to deposition of fluid in the lungs, abdomen, liver, and lower body. CHF is treated by a number of devices that maintain heart rhythm, such as pacemakers, cardiac resynchronization therapy CRT, implantable cardioverter defibrillators ICDs, and ventricular assist devices VADs.nbsp;nnThe world CHF treatment devices market was evaluated at $10,127.2 million in 2015, and is estimated to reach $14,823.3 million by 2022, with a CAGR of 5.5% over the forecast period. This is primarily attributed to the constantly changing lifestyle habits such as unhealthy dietary habits, excessive alcohol consumption, smoking, obesity, and lack of physical activity which make individuals more susceptible to arrhythmia and heart failure. In addition, a number of factors such as the large number of technological advancements in CHF treatment devices, increased adoption rate of these devices, and rising emphasis on early intervention and primary prevention of heartrelated disorders are responsible for driving the market. Conversely, stringent government regulations for the approval of CHF treatment devices, high cost of, and high preference to drugs for CHF treatment are some of the factors restraining the market growth.nnThe report segments the world CHF treatment devices market based on product type, namely, pacemakers, cardiac resynchronization therapy CRT devices, implantable cardioverter defibrillators ICDs, and ventricular assist devices VADs. Pacemaker is further segmented into dualchamber pacemakers and singlechamber pacemakers. CRT devices is segmented into two major types, namely, CRTP and CRTD. ICDs is further segmented into transvenous implantable cardioverter defibrillator TICDs and subcutaneous implantable cardioverter defibrillator SICDs. VADs is also segmented into left ventricular assist device LVAD, right ventricular assist device RVAD, and biventricular assist device BIVAD. ICDs was the highest revenuegenerating segment in 2015, owing to the stressful hyperactive lifestyle, unhealthy food habits, and growing number of aging population. Based on geography, the market is divided into North America, Europe, AsiaPacific, and LAMEA regions.nbsp;nnThe key players in this market adopted product development and product launch as their key strategies to keep pace with the changing demands of consumers. Furthermore, companies launched costeffective and technologically efficient products to strengthen their market position. The report provides a comprehensive analysis of the key players operating in the world CHF treatment devices market, such as Abiomed, Inc., Berlin Heart GmbH, Biotronik SE amp; Co. KG, Boston Scientific Corporation, HeartWare International, Inc., Jarvik Heart, Inc., LivaNova PLC, Medtronic plc, ReliantHeart Inc., and St. Jude Medical, Inc.nnKey BenefitsnnnnThe study provides an indepth analysis of the world CHF treatment devices market with current trends and future estimations to elucidate the imminent investment pockets in the market.nnThe report provides a quantitative analysis from 2015 to 2022 that would enable the stakeholders to capitalize on prevailing market opportunities.nnExtensive analysis of the world CHF treatment devices market, by product, helps in understanding the various types of devices used for the treatment of CHF and other related cardiac conditions.nbsp;nnCompetitive intelligence highlights the business practices followed by leading market players across various geographic regions.nnSWOT analysis enables to study the internal environment of the leading companies for strategy formulation.nnnCONGESTIVE HEART FAILURE CHF TREATMENT DEVICES MARKET KEY SEGMENTS:nnCongestive Heart Failure CHF Treatment Devices Market, By ProductnnnnnnPacemakers, By TypennnnnnImplantable PacemakersnnnExternal PacemakersnnnnnnnnCardiac Resynchronization Therapy CRT, By TypennnnnnCardiac Resynchronization TherapyPacemakers CRTPnnnCardiac Resynchronization TherapyDefibrillators CRTDnnnnnnnnImplantable Cardioverter Defibrillators ICDs, By TypennnnnnTransvenous Implantable Cardioverter Defibrillator TICDsnnnSubcutaneous Implantable Cardioverter Defibrillator SICDsnnnnnnnnVentricular Assist Devices VADs, By TypennnnnnLeft Ventricular Assist Device LVADnnnRight Ventricular Assist Device RVADnnnBiventricular Assist Device BIVADnnnnnnnBy GeographynnnnNorth AmericannnnnnU.S.nnnCanadannnMexiconnnnnnEuropennnnnGermanynnnU.K.nnnFrancennnRest of EuropennnnnnAsiaPacificnnnnnJapannnnChinannnIndiannnRest of AsiaPacificnnnnnnLAMEAnnnnnLatin AmericannnMiddle EastnnnAfricannnnnNEXT ARTICLE
Cardiology is a specialty of internal medicine. Cardiac electrophysiology : Study of the electrical properties and conduction diseases of the heart. Echocardiography : The use of ultrasound to study the mechanical function/physics of the h...
Hepatology is the study of liver, gallbladder, biliary tree, and pancreas, and diseases associated with them. This includes viral hepatitis, alcohol damage, cirrhosis and cancer. As modern lifestyles change, with alcoholism and cancer becoming more promi...